Nintedanib in patients with progressive fibrosing ILDs in subgroups by comorbidity burden

被引：0
|
作者：
Bendstrup, E. [1 ]
Moua, T. [2 ]
Okamoto, M. [3 ]
Tomassetti, S. [4 ]
Valenzuela, C. [5 ]
Wuyts, A. [6 ]
Miede, C. [7 ]
Lievens, D. [8 ]
Bonella, F. [9 ]
机构：
[1] Aarhus Univ Hosp, Dept Resp Dis & Allergy, Ctr Rare Lung Dis, Aarhus, Denmark
[2] Mayo Clin Rochester, Div Pulm & Crit Care Med, Rochester, MN USA
[3] Kurume Univ, Sch Med, Dept Internal Med, Div Respirol Neurol & Rheumatol, Kurume, Fukuoka, Japan
[4] Careggi Univ Hosp, Dept Expt & Clin Med, Florence, Italy
[5] Univ Autonoma Madrid, Hosp Univ Princesa, Madrid, Spain
[6] Univ Hosp Leuven, Dept Pulm Med, Unit Interstitial Lung Dis, Leuven, Belgium
[7] Mainanalytics GmbH, Sulzbach, Taunus, Germany
[8] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[9] Univ Duisburg Essen, Pneumol Dept, Ctr Interstitial & Rare Lung Dis, Ruhrlandklin, Essen, Germany
来源：
EUROPEAN RESPIRATORY JOURNAL | 2022年 / 60卷
关键词：
D O I：
10.1183/13993003.congress-2022.615
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Continued nintedanib treatment in patients with progressive fibrosing ILDs: interim analysis of INBUILD-ON
    Bonella, F.
    Wuyts, A. W.
    Chaudhuri, N.
    Varone, F.
    Antin-Ozerkis, D.
    Mueller, H.
    Coeck, C.
    Rohr, B. K.
    Cottin, V
    PNEUMOLOGIE, 2022, 76 : S25 - S26
  • [2] Efficacy and Safety of Nintedanib in Elderly Patients with Progressive Fibrosing Interstitial Lung Diseases (ILDs)
    Moua, T.
    Bonella, F.
    Okamoto, M.
    Tomassetti, S.
    Valenzuela, C.
    Wuyts, W.
    Miede, C.
    Lievens, D.
    Bendstrup, E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [3] Continued nintedanib treatment in patients with progressive fibrosing ILDs: interim analysis of INBUILD-ON
    Wuyts, Wim A.
    Bonella, Francesco
    Chaudhuri, Nazia
    Varone, Francesco
    Antin-Ozerkis, Danielle
    Mueller, Heiko
    Coeck, Carl
    Rohr, Klaus B.
    Cottin, Vincent
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [4] Continued nintedanib treatment in patients with progressive fibrosing ILDs: interim analysis of INBUILD-ON
    Wuyts, W. A.
    Bonella, F.
    Chaudhuri, N.
    Varone, F.
    Antin-Ozerkis, D.
    Mueller, H.
    Coeck, C.
    Rohr, K. B.
    Cottin, V
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [5] Efficacy and safety of nintedanib in elderly patients with progressive fibrosing interstitial lung diseases (ILDs)*
    Bonella, Autoren F.
    Moua, T.
    Okamoto, M.
    Tomassetti, S.
    Valenzuela, C.
    Wuyts, W.
    Miede, C.
    Lievens, D.
    Bendstrup, E.
    PNEUMOLOGIE, 2023, 77 : S57 - S57
  • [6] Characteristics of Patients with Progressive Fibrosing Interstitial Lung Diseases (ILDs) in the INBUILD Trial of Nintedanib
    Flaherty, K. R.
    Wells, A. U.
    Clerisme-Beaty, E.
    Cottin, V.
    Devaraj, A.
    Inoue, Y.
    Richeldi, L.
    Walsh, S.
    Goeldner, R.
    Schlenker-Herceg, R.
    Brown, K. K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [7] Effect of Nintedanib on FVC Decline in Patients with Progressive Fibrosing ILDs: Data from the INBUILD Trial
    Cottin, V.
    Inoue, Y.
    Kolb, M.
    Rosas, I.
    Tomassetti, S.
    Quaresma, M.
    Goeldner, R.
    Schlenker-Herceg, R.
    Brown, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [8] Effects of nintedanib on progression of ILD in patients with fibrosing ILDs and a progressive phenotype: further analyses of the INBUILD trial
    Koschel, D.
    Flaherty, K. R.
    Wells, A. U.
    Cottin, V
    Devaraj, A.
    Inoue, Y.
    Richeldi, L.
    Walsh, S. L. F.
    Kolb, M.
    Moua, T.
    Stowasser, S.
    Goeldner, R. G.
    Schlenker-Herceg, R.
    Brown, K. K.
    PNEUMOLOGIE, 2021, 75 : S30 - S31
  • [9] Effects of Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-related Interstitial Lung Diseases (ILDs) in the INBUILD Trial: Subgroups by HRCT Pattern
    Dellaripa, Paul
    Aringer, Martin
    Mann-Vold, Anna Maria Hoff
    Kelly, Clive
    Mittoo, Shikha
    James, Alexandra
    Rohr, Klaus
    Stowasser, Susanne
    Inoue, Yoshikazu
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [10] Effects of nintedanib in patients with progressive fibrosing ILDs and differing baseline FVC: further analyses of the INBUILD trial
    Valenzuela, Claudia
    Maher, Toby M.
    Bonella, Francesco
    Pesci, Alberto
    Jouneau, Stephane
    Patel, Nina M.
    Perez, Evans R. Fernandez
    Goeldner, Rainer-Georg
    Stowasser, Susanne
    Schlenker-Herceg, Rozsa
    Quaresma, Manuel
    Cottin, Vincent
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
12345